LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MRSA Identified Using Nasal Swabs

By LabMedica International staff writers
Posted on 13 Sep 2012
Methicillin-resistant Staphylococcus aureus (MRSA) infections have been detected by nasal swabbing using agar culture methods.

The proportion of patients with MRSA that were correctly identified by nasal swabs has been compared with multiple body site testing using agar and nutrient broth culture.

A cross-sectional study has been carried out by the Health Protection Scotland (Glasgow, UK) on adult patients admitted to 36 general specialty wards of two large hospitals in Scotland (UK). Patients were screened for MRSA via multiple body site swabs such as nasal, throat, axillary, perineal, wound, and invasive device sites. These were cultured individually on Brilliance MRSA chromogenic agar (Oxoid; Basingstoke, UK) and pooled in nutrient broth. Suspect colonies were confirmed by a coagulase test using the Prolex Staph Xtra Latex kit (Pro-Lab Diagnostics; Bromborough, UK). Combined results from all sites and cultures provided a gold-standard estimate of true MRSA prevalence.

The scientist found that nasal screening performed better than throat, axillary, or perineal screening, but only identified 66% of true MRSA carriers against the gold standard at an overall prevalence of 2.9%. Axillary screening performed least well. Combining nasal and perineal swabs gave the best two-site combination with 82%. When combined with realistic screening compliance rates of 80%-90%, nasal swabbing alone probably detects just over half of true colonization in practice. Swabbing of clinically relevant sites such as wounds and indwelling devices, is important for a small but high-prevalence group.

The investigators concluded that nasal swabbing is the standard method in many locations for MRSA screening. Its diagnostic efficiency in practice appears to be limited, however, and the resource implications of multiple body site screening have to be balanced against a potential clinical benefit whose magnitude and nature remains unclear. The study was published in the August 2012 issue of the journal Infection Control and Hospital Epidemiology.

Related Links:

Health Protection Scotland
Oxoid
Pro-Lab Diagnostics


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
All-in-One Molecular System
AIO M160

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM